Buscador de publicaciones

Publicaciones

  • Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell-Burriel M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives-Solà S and Pérez-Simón JA.

    Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

    FRONTIERS IN IMMUNOLOGY . 14: 1280580-1280580.

    [doi:10.3389/fimmu.2023.1280580]

  • Marina Caballero Bellón, Alonso-Saladrigues A, Bobillo-Perez S, Faura A, Arqués L, Rivera C, Català-Temprano A, Dapena JL, Rives-Solà S and Jordán-García I.

    Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

    FRONTIERS IN IMMUNOLOGY . 14: 1219289-1219289.

    [doi:10.3389/fimmu.2023.1219289]

  • Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, Català-Temprano A, Benítez-Ribas D, Giné E, Díaz-Beyá M, Correa JG, Rovira M, Montoro-Lorite M, Martínez-Roca A, Rodríguez-Lobato LG, Cabezón R, Cid J, Lozano M, Garcia-Rey E, Conde N, Pedrals G, Rozman M, Torrebadell-Burriel M, Setoain X, Rodríguez S, Esteve J, Pascal M, Urbano-Ispizua Á, Juan-Otero M, Delgado J and Rives-Solà S.

    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease

    AMERICAN JOURNAL OF HEMATOLOGY . 97(6): 731-739. Nº de citas: 2

    [doi:10.1002/ajh.26519]

  • Marina Caballero Bellón, Faura A, Margarit A, Bobillo-Perez S, Català-Temprano A, Alonso-Saladrigues A, Conde N, Balaguer-Gargallo M, Rives-Solà S and Jordán-García I.

    Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit

    EUROPEAN JOURNAL OF PEDIATRICS . 181(3): 1037-1045. Nº de citas: 3

    [doi:10.1007/s00431-021-04292-9]

  • Ortiz-Maldonado V, Rives-Solà S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català-Temprano A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordán-García I, Villamor N, Aymerich M, Torrebadell-Burriel M, Deyà-Martinez A, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan-Otero M and Delgado J.

    Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

    Journal for ImmunoTherapy of Cancer . 9(12): 3644. Nº de citas: 9

    [doi:10.1136/jitc-2021-003644]

  • Mesegue-Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, Dapena JL, Faura A, Conde N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M and Rives-Solà S.

    Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.

    HEMATOLOGICAL ONCOLOGY . 39(5): 687-696. Nº de citas: 4

    [doi:10.1002/hon.2914]

  • Ortíz-Maldonado V, Rives-Solà S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Jordi Cid Colom, Garcia-Rey E, Llanos C, Torrebadell-Burriel M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català-Temprano A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordán-García I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan-Otero M and Delgado J.

    CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies

    MOLECULAR THERAPY . 29(2): 636-644. Nº de citas: 68

    [doi:10.1016/j.ymthe.2020.09.027]

  • Deyà-Martinez A, Alonso-Saladrigues A, Garcia, A. P., Faura, A., Torrebadell-Burriel M, Vlagea, A., Català-Temprano A, Esteve-Solé A, Juan-Otero M, Rives-Solà S and Alsina L.

    Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia

    BONE MARROW TRANSPLANTATION . 56(2): 376-386. Nº de citas: 12

    [doi:10.1038/s41409-020-01027-6]

  • Vega-García N, Malatesta R, Estella-Aguado MC, Pérez-Jaume S, Esperanza-Cebollada E, Torrebadell-Burriel M, Català-Temprano A, Gassiot S, Berrueco R, Ruiz-Llobet A, Alonso-Saladrigues A, Mesegue-Meda M, Pont-Martí S, Rives-Solà S and Camós-Guijosa M.

    Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases

    BRITISH JOURNAL OF HAEMATOLOGY . 182(4): 542-553. Nº de citas: 7

    [doi:10.1111/bjh.15436]

  • Berrueco R, Alonso-Saladrigues A, Martorell-Sampol L, Català-Temprano A, Ruiz-Llobet A, Toll T, Torrebadell-Burriel M, Naudo-Lahoz M, Camós-Guijosa M and Rives-Solà S.

    Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening

    PEDIATRIC BLOOD & CANCER . 62(7): 1195-1201. Nº de citas: 8

    [doi:10.1002/pbc.25457]